Stockscreener 앱 받기
1.34
0.00%
0.00
전일 마감가:
$1.34
열려 있는:
$1.37
하루 거래량:
64,513
Relative Volume:
0.88
시가총액:
$5.39M
수익:
-
순이익/손실:
$-7.10M
주가수익비율:
-0.2525
EPS:
-5.3059
순현금흐름:
$-8.30M
1주 성능:
+0.00%
1개월 성능:
+12.61%
6개월 성능:
-35.58%
1년 성능:
-81.38%
1일 변동 폭
$1.28
$1.37
1주일 범위
$1.27
$1.52
52주 변동 폭
$1.10
$8.00
Dermata Therapeutics Inc Stock (DRMA) Company Profile
명칭
Dermata Therapeutics Inc
전화
(858)-223-0882
주소
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.34 | 5.39M | 0 | -7.10M | -8.30M | -5.3059 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dermata Therapeutics Inc 주식(DRMA)의 최신 뉴스
Dermata Therapeutics Inc Warrant 2021- on Dermata Therapeutics Financial Disclosures & SEC Filings - TradingView
Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 – Warrants Remain at Key Support LevelCombination Correction - dars.gov.et
Price to earnings forward of Dermata Therapeutics, Inc. – BOATS:DRMAW - TradingView
Dermata Therapeutics, Inc. Actuals & Estimates (NASDAQ:DRMA) - TradingView
Enterprise value to EBIT forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
DRMA Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
Dermata Therapeutics Inc (DRMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dermata Therapeutics Inc (DRMAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lixte Biotechnology Holdings, Inc. (LIXTW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dermata Therapeutics Inc (DRMA) Institutional Confidence - TradingKey
Dermata Therapeutics Inc (DRMAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dermata Therapeutics Inc (DRMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dermata Therapeutics Inc (DRMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dermata Therapeutics Inc (DRMAW) Institutional Confidence - TradingKey
Dermata Therapeutics Inc (DRMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dermata Therapeutics Inc (DRMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dermata Therapeutics Inc (DRMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dermata Therapeutics Inc - TradingKey
Dermata Therapeutics Inc (DRMAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dermata Therapeutics Inc (DRMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dermata Therapeutics (NASDAQ: DRMA) director reports small open-market stock sale - Stock Titan
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment - timothysykes.com
Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch - timothysykes.com
Dermata Therapeutics Warrant (DRMAW) Slides 19.73% as Price Nears Critical Floor at $0.01Dark Pool Volume - newsline.com
DRMA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Control Amid Pipeline ProgressQuarterly Financial Update - newsline.com
DRMA Q1 2026 Earnings: Better-than-Expected Loss Reduction Amidst Pipeline Development FocusShare Dilution Risk - newsline.com
DRMA Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Advances ContinueSlow Growth Warning - newsline.com
Dermata Therapeutics (DRMA) Edges Higher as Stock Tests Key Resistance LevelsVolume Climax - newsline.com
DRMA Q1 2026 Earnings: Positive EPS Surprise as Dermata Advances PipelinePreliminary Results - newsline.com
CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D - Stock Titan
[EFFECT] Dermata Therapeutics, Inc. SEC Filing - Stock Titan
Dermata Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Dermata Therapeutics Warrant (DRMAW) Holds at Penny Level – Key Levels to WatchPoint of Control - newsline.com
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration - Stock Titan
Dermata Therapeutics (DRMA) Stages Modest Recovery – Support Holds Above $1.28Keltner Channel - The Legal Advocate
Dermata Therapeutics (DRMA) Shares Climb 3.85% as Stock Tests Key Resistance LevelsVolume Breakout Ideas - The Legal Advocate
Dermata Therapeutics Adopts Fourth Amendment to 2021 Omnibus Equity Incentive Plan – Form 8-K Filing Summary - Minichart
Dermata Therapeutics Shareholders Approve Equity Plan and Directors - TipRanks
Dermata (NASDAQ: DRMA) investors approve equity plan expansion and warrant changes - Stock Titan
DRMADermata Therapeutics Inc Stock Price and Quote - Finviz
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
DRMA Q1 2026 Earnings: Narrower Loss Than Expected Bolsters Investor SentimentRevenue Report - Newser
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants - Stock Titan
DRMA Q1 2026 Earnings: Narrower-than-Expected Loss Marks Progress for Clinical-Stage BiotechEarnings Yield Spread - The Legal Advocate
Dermata Therapeutics (DRMA) Slides 0.8% as Shares Hover Near Support at $1.18Virgin POC - Newser
Dermata Therapeutics Inc (DRMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Dermata Therapeutics Inc 주식 (DRMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bedoya-Toro Munera Maria E | SVP, Regulatory Affairs |
Feb 17 '26 |
Buy |
1.27 |
1,000 |
1,270 |
1,012 |
2.64%
자본화:
|
볼륨(24시간):